Linkage of Type I Interferon Activity and TNF-Alpha Levels in Serum with Sarcoidosis Manifestations and Ancestry

Background Both type I interferon (IFN), also known as IFN-α and tumor necrosis factor alpha (TNF-α) have been implicated in the pathogenesis of sarcoidosis. We investigated serum levels of these cytokines in a large multi-ancestral sarcoidosis population to determine correlations between cytokine levels and disease phenotypes. Methods We studied serum samples from 98 patients with sarcoidosis, including 71 patients of African-American ancestry and 27 patients of European-American ancestry. Serum type I IFN was measured using a sensitive reporter cell assay and serum TNF-α was measured using a commercial ELISA kit. Clinical data including presence or absence of neurologic, cardiac, and severe pulmonary manifestations of sarcoidosis were abstracted from medical records. Twenty age-matched non-autoimmune controls were also studied from each ancestral background. Differences in cytokine levels between groups were analyzed with Mann-Whitney U test, and correlations were assessed using Spearman's rho. Multivariate logistic regression models were used to detect associations between cytokines and clinical manifestations. Results Significant differences in cytokine levels were observed between African- and European-American patients with sarcoidosis. In African-Americans, serum TNF-α levels were significantly higher relative to matched controls (P = 0.039), and patients with neurologic disease had significantly higher TNF-α than patients lacking this manifestation (P = 0.022). In European-Americans, serum type I IFN activity was higher in sarcoidosis cases as compared to matched controls, and patients with extra-pulmonary disease represented a high serum IFN subgroup (P = 0.0032). None of the associations observed were shared between the two ancestral groups. Conclusions Our data indicate that significant associations between serum levels of TNF-α and type I IFN and clinical manifestations exist in a sarcoidosis cohort that differ significantly by self-reported ancestry. In each ancestral background, the cytokine elevated in patients with sarcoidosis was also associated with a particular disease phenotype. These findings may relate to ancestral differences in the molecular pathogenesis of this heterogeneous disease.

[1]  R. Freire,et al.  Interferon-induced sarcoidosis , 2011, BMJ Case Reports.

[2]  W. Hamdi,et al.  [Rheumatologic manifestations of sarcoidosis]. , 2010, La Tunisie medicale.

[3]  F. Zoulim,et al.  Sarcoidosis and hepatitis C: clinical description of 11 cases , 2010, European journal of gastroenterology & hepatology.

[4]  A. Skol,et al.  Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus , 2010, Arthritis research & therapy.

[5]  Timothy B. Niewold,et al.  Interferon Alpha in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.

[6]  H. Tumani,et al.  Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis , 2010, Journal of Neurology.

[7]  R. Baughman,et al.  TNF Inhibition As Novel Therapy For Refractory Sarcoidosis: Long Term Follow Up , 2010, ATS 2010.

[8]  J. del Pozo,et al.  Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C , 2010, Dermatology research and practice.

[9]  T. Niewold,et al.  Genetic regulation of serum cytokines in systemic lupus erythematosus. , 2010, Translational research : the journal of laboratory and clinical medicine.

[10]  P. Boumier,et al.  Cutaneous Sarcoidosis Occurring during Anti-TNF-Alpha Treatment: Report of Two Cases , 2010, Dermatology.

[11]  J. Garcia,et al.  Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations , 2010, PloS one.

[12]  L. Cavazzini,et al.  Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. , 2010, Seminars in arthritis and rheumatism.

[13]  M. Jolly,et al.  Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. , 2010, Arthritis and rheumatism.

[14]  V. Pascual,et al.  Systemic sclerosis and lupus: points in an interferon-mediated continuum. , 2010, Arthritis and rheumatism.

[15]  S. Moreno-Swirc,et al.  Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient. , 2009, Joint, bone, spine : revue du rhumatisme.

[16]  陶仲为 Sarcoidosis , 2009 .

[17]  A. Giannetti,et al.  Cutaneous lesions as initial signs of interferon α‐induced sarcoidosis: report of three new cases and review of the literature , 2009, Dermatologic therapy.

[18]  J. Olerud,et al.  Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C. , 2009, Journal of Drugs in Dermatology.

[19]  S. Pavy,et al.  Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. , 2009, Rheumatology.

[20]  T. Niewold,et al.  Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. , 2009, Arthritis and rheumatism.

[21]  B. Segal,et al.  Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil , 2009, Neurology.

[22]  S. Garg,et al.  Refractory vertebral sarcoidosis responding to infliximab. , 2008, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[23]  T. Niewold Interferon alpha-induced lupus: proof of principle. , 2008, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[24]  J. Buyon,et al.  Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. , 2008, Arthritis and rheumatism.

[25]  S. Pillemer,et al.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. , 2007, Arthritis and rheumatism.

[26]  R. Baughman,et al.  Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? , 2007, The Journal of rheumatology.

[27]  J. Harley,et al.  High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus , 2007, Genes and Immunity.

[28]  R. Baughman,et al.  Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. , 2007, Clinics in dermatology.

[29]  R. Inman,et al.  Pulmonary sarcoidosis developing during infliximab therapy. , 2006, Arthritis and rheumatism.

[30]  B. Sands,et al.  A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. , 2006, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[31]  R. D. du Bois,et al.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. , 2006, American journal of respiratory and critical care medicine.

[32]  M. Crow,et al.  Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. , 2006, Arthritis and rheumatism.

[33]  M. Atkins,et al.  Autoimmunity and immunotherapy for cancer. , 2006, The New England journal of medicine.

[34]  J. Curran,et al.  Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. , 2005, Arthritis and rheumatism.

[35]  L. Rönnblom,et al.  Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. , 2005, Arthritis and rheumatism.

[36]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[37]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Ramos-Casals,et al.  Extrahepatic manifestations in patients with chronic hepatitis C virus infection. , 2008 .

[39]  T. Niewold,et al.  Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C , 2005, Clinical Rheumatology.

[40]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[41]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[42]  C. Yurdaydın,et al.  Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. , 2000, Hepato-gastroenterology.

[43]  H. Magnussen,et al.  Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. , 1993, The Journal of allergy and clinical immunology.

[44]  R. Baughman,et al.  Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. , 1990, The Journal of laboratory and clinical medicine.

[45]  D. James Sarcoidosis around the world. , 1988, Postgraduate medical journal.